Segment Reporting

12 Months Ended

Jun. 30, 2025

Statements [Line Items]

Segment Reporting

NOTE 4. SEGMENT REPORTING

Identification of reportable operating segments

Operating segments are reported in a manner consistent with internal reports which are reviewed and used by Management and the Board of Directors (who are identified as the Chief Operating Decision Makers (‘CODM’)). The Group operates in one operating segment, being Cancer Immunotherapy.

Operating segment information June 30, 2025	Immunotherapy A$			Unallocated A$		Consolidated A$
Revenue
License revenue		—			—		—
Other income
Research material sales		59,709			—		59,709
Grant income		4,974,823			—		4,974,823
Miscellaneous income		—			390		390
Net change on fair value movement		—			9,242		9,242
Interest income		—			5,287,209		5,287,209
Total revenue and other income		5,034,532			5,296,841		10,331,373
Result
Segment Result		(65,020,504	)		3,586,339		(61,434,165	)
Profit/(loss) before income tax expense		(65,020,504	)		3,586,339		(61,434,165	)
Income tax expense		—			—		—
Loss after income tax expense							(61,434,165	)
Total segment assets		156,983,434			—		156,983,434
Total segment liabilities		13,348,071			—		13,348,071

Operating segment information June 30, 2024	Immunotherapy A$			Unallocated A$		Consolidated A$
Revenue
License revenue		—			—		—
Other income
Research material sales		119,089			—		119,089
Grant income		3,722,788			—		3,722,788
Net gain on fair value movement of warrants		—			—		—
Net gain on foreign exchange		—			113,458		113,458
Interest income		—			3,882,757		3,882,757
Total revenue and other income		3,841,877			3,996,215		7,838,092
Result
Segment Result		(46,556,929	)		3,840,304		(42,716,625	)
Profit/(loss) before income tax expense		(46,556,929	)		3,840,304		(42,716,625	)
Income tax expense		—			—		—
Loss after income tax expense							(42,716,625	)
Total segment assets		201,579,281			—		201,579,281
Total segment liabilities		12,057,539			—		12,057,539

Operating segment information June 30, 2023	Immunotherapy A$			Unallocated A$		Consolidated A$
Revenue
License revenue		—			—		—
Other income
Research material sales		191,721			—		191,721
Grant income		3,314,001			—		3,314,001
Net gain on fair value movement of warrants		—			131,896		131,896
Net gain on foreign exchange		—			623,511		623,511
Interest income		—			938,999		938,999
Total revenue and other income		3,505,722			1,694,406		5,200,128
Result
Segment Result		(41,431,305	)		1,534,957		(39,896,348	)
Profit/(loss) before income tax expense		(41,431,305	)		1,534,957		(39,896,348	)
Income tax expense		—			—		—
Loss after income tax expense							(39,896,348	)
Total segment assets		147,448,990			—		147,448,990
Total segment liabilities		10,979,601			—		10,979,601